© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 20, 1569-1575,
October 16, 2002
© 2002 Oxford University Press
ARTICLE |
VHL Tumor Suppressor Gene Alterations Associated With Good Prognosis in Sporadic Clear-Cell Renal Carcinoma
Affiliations of authors: M. Yao, M. Yoshida, T. Kishida, N. Nakaigawa, M. Baba, K. Kobayashi, Y. Kubota, K. Kondo (Department of Urology), Y. Nagashima (Department of Pathology), Yokohama City University School of Medicine, Yokohama, Japan; T. Miura, Department of Urology, Kanagawa Cancer Center, Yokohama; M. Moriyama, Department of Urology, Yokohama City Municipal Hospital, Yokohama; Y. Nakatani, Department of Anatomical and Surgical Pathology, Yokohama City University Hospital, Yokohama.
Correspondence to: Masahiro Yao, M.D., Ph.D., Department of Urology, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004 Japan (e-mail: masayao{at}med.yokohama-cu.ac.jp).
Background: Somatic alteration of the von Hippel–Lindau disease tumor suppressor gene (VHL) is one of the most common genetic changes observed in the sporadic, clear-cell subtype of renal cell carcinoma (RCC). However, the prognostic utility of VHL mutations has not been examined. The purpose of this study was to explore the association between VHL mutations and the risk of death from sporadic clear-cell RCC. Methods: A total of 187 Japanese patients with clear-cell RCC who underwent nephrectomy from October 1986 through December 1995 were examined for somatic VHL gene alteration. Clinicopathologic and survival data were also collected. Kaplan–Meier analyses and Cox proportional hazards models were used to explore associations. All statistical tests were two-sided. Results: A VHL alteration (mutation or hypermethylation) was detected in 108 RCC tumor samples: intragenic mutations in 98 (52%) and hypermethylation in 10 (5.3%). VHL alterations were strongly associated with better cancer-free survival and cancer-specific survival for the 134 patients with stage I–III clear-cell RCC treated by radical nephrectomy (log-rank P = .024 and .023, respectively). These associations were more statistically significant among patients with relatively advanced disease (stage III [P = .014 and .010, respectively] or stage II + III [P = .002 and .009]) or higher grade tumors (G3 or higher [P = .013 and .032] or G2 or higher [P = .013 and .018]) and among patients who presented with symptoms (P = .005 and .012). VHL alterations remained an independent prognostic factor for patients with stage I–III tumors after adjustment for sex, age, stage, grading, and symptomatic presentation. VHL alterations were not associated with cancer-specific survival for the 53 patients with stage IV tumors treated with palliative or adjunctive nephrectomy (log-rank P = .760). Conclusion: The VHL alteration status may provide useful prognostic information, as a biomolecular marker, for patients with stage I–III clear-cell RCC who have undergone nephrectomy.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  O. Mikhaylova, M. L. Ignacak, T. J. Barankiewicz, S. V. Harbaugh, Y. Yi, P. H. Maxwell, M. Schneider, K. Van Geyte, P. Carmeliet, M. P. Revelo, et al. The von Hippel-Lindau Tumor Suppressor Protein and Egl-9-Type Proline Hydroxylases Regulate the Large Subunit of RNA Polymerase II in Response to Oxidative Stress Mol. Cell. Biol., April 15, 2008; 28(8): 2701 - 2717. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Smits, L. J. Schouten, B. A.C. van Dijk, C. A. Hulsbergen-van de Kaa, K. A.D. Wouters, E. Oosterwijk, M. van Engeland, and P. A. van den Brandt Genetic and Epigenetic Alterations in the von Hippel-Lindau Gene: the Influence on Renal Cancer Prognosis Clin. Cancer Res., February 1, 2008; 14(3): 782 - 787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Costa and H. A. Drabkin Renal Cell Carcinoma: New Developments in Molecular Biology and Potential for Targeted Therapies Oncologist, December 1, 2007; 12(12): 1404 - 1415. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Shinojima, M. Oya, A. Takayanagi, R. Mizuno, N. Shimizu, and M. Murai Renal cancer cells lacking hypoxia inducible factor (HIF)-1{alpha} expression maintain vascular endothelial growth factor expression through HIF-2{alpha} Carcinogenesis, March 1, 2007; 28(3): 529 - 536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yao, Y. Huang, K. Shioi, K. Hattori, T. Murakami, N. Nakaigawa, T. Kishida, Y. Nagashima, and Y. Kubota Expression of Adipose Differentiation-Related Protein: A Predictor of Cancer-Specific Survival in Clear Cell Renal Carcinoma Clin. Cancer Res., January 1, 2007; 13(1): 152 - 160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-i. Shioi, A. Komiya, K. Hattori, Y. Huang, F. Sano, T. Murakami, N. Nakaigawa, T. Kishida, Y. Kubota, Y. Nagashima, et al. Vascular Cell Adhesion Molecule 1 Predicts Cancer-Free Survival in Clear Cell Renal Carcinoma Patients Clin. Cancer Res., December 15, 2006; 12(24): 7339 - 7346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Banks, P. Tirukonda, C. Taylor, N. Hornigold, D. Astuti, D. Cohen, E. R. Maher, A. J. Stanley, P. Harnden, A. Joyce, et al. Genetic and Epigenetic Analysis of von Hippel-Lindau (VHL) Gene Alterations and Relationship with Clinical Variables in Sporadic Renal Cancer Cancer Res., February 15, 2006; 66(4): 2000 - 2011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Nakamura, P. Abreu-e-Lima, Y. Awakura, T. Inoue, T. Kamoto, O. Ogawa, H. Kotani, T. Manabe, G.-J. Zhang, K. Kondo, et al. Clusterin Is a Secreted Marker for a Hypoxia-Inducible Factor-Independent Function of the von Hippel-Lindau Tumor Suppressor Protein Am. J. Pathol., February 1, 2006; 168(2): 574 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. H. Frey, G. Lummen, T. Jager, K.-H. Jockel, K. W. Schmid, H. Rubben, N. Muller, W. Siffert, and A. Eisenhardt The GNAS1 T393C Polymorphism Predicts Survival in Patients with Clear Cell Renal Cell Carcinoma Clin. Cancer Res., February 1, 2006; 12(3): 759 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. G. Kaelin Jr. The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer Clin. Cancer Res., September 15, 2004; 10(18): 6290S - 6295S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Lam, A. S. Belldegrun, and R. A. Figlin Tissue Array-Based Predictions of Pathobiology, Prognosis, and Response to Treatment for Renal Cell Carcinoma Therapy Clin. Cancer Res., September 15, 2004; 10(18): 6304S - 6309S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-H. Tan, C. G. Rogers, J. T. Cooper, J. A. Ditlev, T. J. Maatman, X. Yang, K. A. Furge, and B. T. Teh Gene Expression Profiling of Renal Cell Carcinoma Clin. Cancer Res., September 15, 2004; 10(18): 6315S - 6321S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Dancey Epidermal Growth Factor Receptor and Epidermal Growth Factor Receptor Therapies in Renal Cell Carcinoma: Do We Need a Better Mouse Trap? J. Clin. Oncol., August 1, 2004; 22(15): 2975 - 2977. [Full Text] [PDF]
|
|
|
|
 |
|
 A M Jubb, T Q Pham, A M Hanby, G D Frantz, F V Peale, T D Wu, H W Koeppen, and K J Hillan Expression of vascular endothelial growth factor, hypoxia inducible factor 1{alpha}, and carbonic anhydrase IX in human tumours J. Clin. Pathol., May 1, 2004; 57(5): 504 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Sosman Targeting of the VHL-Hypoxia-Inducible Factor-Hypoxia-Induced Gene Pathway for Renal Cell Carcinoma Therapy J. Am. Soc. Nephrol., November 1, 2003; 14(11): 2695 - 2702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Pantuck, G. Zeng, A. S. Belldegrun, and R. A. Figlin Pathobiology, Prognosis, and Targeted Therapy for Renal Cell Carcinoma: Exploiting the Hypoxia-Induced Pathway Clin. Cancer Res., October 15, 2003; 9(13): 4641 - 4652. [Abstract] [Full Text] [PDF]
|
|